Who Can Prescribe Peptides? Prescriber Requirements Explained

Key Takeaways

• Regulatory Status: As of April 2026, compounded peptide therapy requires a valid prescription from a licensed practitioner. MDs, DOs, nurse practitioners, and physician assistants all hold prescriptive authority for peptide compounds, subject to individual state scope-of-practice laws. Some peptides — including BPC-157 as of February 2026 — are classified as FDA Category 2 bulk drug substances, restricting their compounding regardless of who is prescribing. The list of Category 2 peptides is under active FDA review; readers should check individual compound pages for current status.
• Research Stage: Prescriber authority is established law; clinical evaluation standards for peptide therapy are evolving, with major endocrine societies actively defining best practices for prescribing and monitoring
• Availability: Prescription only through licensed providers; compounded peptides dispensed by state-licensed 503A compounding pharmacies pursuant to patient-specific prescriptions from licensed practitioners
• How it works: A licensed practitioner evaluates the patient, documents clinical rationale, and transmits a patient-specific prescription to a licensed 503A compounding pharmacy.
• What the evidence shows: NP and PA prescribing quality is comparable to physician prescribing on most quality indicators; the prescription requirement is described in the regulatory literature as a safety mechanism that links access to clinical oversight.

Peptide therapeutics are a regulated pharmaceutical drug class. A 2017 database analysis by Usmani and colleagues, published in PLOS ONE, catalogued over 200 FDA-approved peptide and protein therapeutics in the THPdb database — compounds ranging from insulin and semaglutide to bremelanotide and tesamorelin. Because peptides are drugs under the Federal Food, Drug, and Cosmetic Act, accessing them by prescription is the legally defined pathway in the United States. The question of who can write that prescription is not rhetorical; it has clinical significance. A prescription from a qualified provider who has evaluated the patient and reviewed relevant laboratory data reflects a different clinical process than a prescription issued without review, even where both meet the minimum legal prescription requirement.

Who Holds Prescriptive Authority for Peptide Therapy

Physicians (MD and DO)

Medical doctors and doctors of osteopathic medicine hold full prescriptive authority in all 50 states and the District of Columbia. For peptide compounds, prescribing physicians are typically endocrinologists, internal medicine physicians, or physicians practicing in functional or integrative medicine — though no specialty restriction limits the legal authority to prescribe. Clinical training, familiarity with the relevant evidence base, and the ability to conduct and interpret the required clinical evaluation are the factors that clinical specialty societies and state medical boards generally reference when assessing prescribing appropriateness for a given peptide compound. The Endocrine Society guideline for adult growth hormone deficiency, authored by Molitch and colleagues and published in the Journal of Clinical Endocrinology and Metabolism in 2011, specifies that clinical evaluation including IGF-1 testing must precede prescribing of GH-axis peptides — a standard that applies regardless of prescriber credential.

Nurse practitioners

Nurse practitioners hold prescriptive authority in all 50 states under state-specific scope-of-practice laws. The scope of that authority — including whether a collaborative practice agreement with a physician is required, and which drug schedules an NP may prescribe — varies by state. As of April 2026, more than 20 states grant NPs full independent prescriptive authority; the remainder require a physician collaboration or supervision agreement. A 2023 StatPearls chapter by Zhang and Patel, "Practitioners and Prescriptive Authority", summarizes nurse practitioner prescriptive authority across U.S. scope-of-practice categories, confirming that NPs operate as legal prescribers for the full formulary in states that grant full practice authority. A 2018 study by Jiao and colleagues in Pharmacotherapy compared prescribing quality across physicians, NPs, and PAs using nationally representative data and found NP prescribing quality to be comparable to physician prescribing on several quality indicators — directly relevant to evaluating whether NP-led peptide prescribing is clinically appropriate. A 2016 cohort study by Marcum and colleagues, published in BMC Health Services Research, examined NP and PA prescribing patterns for new chronic disease medications, reinforcing the appropriateness of non-physician prescribers for ongoing hormonal and peptide therapy management.

Physician assistants

Physician assistants hold prescriptive authority in all U.S. states, with the specific scope — including collaboration or supervision requirements — set by each state's medical or PA board. A 2006 review by Cipher, Hooker, and Guerra in the Journal of the American Academy of Nurse Practitioners described the sustained growth of PA prescribing across therapeutic categories, including hormone-related compounds, reflecting a decades-long expansion of advanced practice prescriptive roles.

What the Prescription Requirement Actually Requires

Patient-specific evaluation

The prescription requirement under FDCA Section 503A is not a bureaucratic formality. Cabaleiro's 2021 analysis in the International Journal of Pharmaceutical Compounding confirmed that a valid prescription for a specific patient from a licensed practitioner is the foundational legal requirement for compounding pharmacy dispensing. In clinical practice, this means the prescriber must evaluate the patient individually, establish that the compound is appropriate for that patient's specific clinical situation, and document a rationale. Gudeman and colleagues, in a 2013 review published in Drugs in R&D, emphasized that valid prescriptions from licensed practitioners are the key safety mechanism linking compounded products to clinical accountability — not simply a regulatory checkbox. A prescription written without a clinical evaluation, without review of relevant laboratory data, and without documentation of clinical rationale does not meet the standard that makes the prescription meaningful.

Compounding pharmacy oversight

When a licensed prescriber transmits a patient-specific prescription to a 503A compounding pharmacy, the pharmacy is then responsible for compounding the medication under sterile conditions that meet USP Chapter 797 standards. A 2018 review by Pritchett and colleagues in the International Journal of Pharmaceutical Compounding outlined the certification, accreditation, and credentialing standards that distinguish legitimate 503A compounders from noncompliant operations. Yoch, writing in the same journal in 2017, described the FDA's inspection framework for sterile compounding pharmacies — including the documentation, environmental controls, and personnel requirements that licensed pharmacies must maintain. The prescription pathway is, in this sense, a linked regulatory system: prescriber authority, patient evaluation, and pharmacy quality controls function together. Removing any link — whether by prescribing without evaluation, or by obtaining peptides outside the compounding pharmacy system — undermines the protections the system is designed to provide.

Prescriber liability and documentation

Kircik and Siegel, in a 2023 analysis published in the Journal of Clinical and Aesthetic Dermatology, reviewed the clinical and legal considerations in pharmaceutical compounding from the prescriber perspective — covering prescriber liability, documentation requirements, and the legal distinctions between compounded and FDA-approved drugs. The key finding relevant to peptide prescribing: prescribers bear clinical and legal responsibility for the appropriateness of the prescription, the adequacy of patient evaluation, and the accuracy of clinical documentation. This accountability structure is absent in the research peptide channel, where no licensed prescriber, no clinical documentation, and no pharmacy oversight are involved.

Research Peptides Are Not Prescription Peptides

What research-use-only products actually are

Products sold through online vendors as "research use only" or "not for human use" are not medications. They have not been evaluated for pharmaceutical-grade purity, sterility, or accurate dosing. They are not dispensed by licensed pharmacies. No prescription is required to obtain them, precisely because they are not regulated as drugs for human use. The Obesity Medicine Association addressed the prescribing landscape for compounded peptides in a 2024 FAQ document authored by Bays and colleagues, published in Obesity Pillars, calling for regulatory clarity on compounded peptide prescribing — a signal that major medical societies are actively distinguishing between prescription-pathway peptides and unregulated market products.

Documented risks of unregulated peptide products

The safety disparity between prescription and non-prescription peptide channels is documented in peer-reviewed literature. Vanhee and colleagues, publishing in Talanta in 2015, analyzed illegal peptide biopharmaceuticals seized from non-prescription channels and found significant dose inaccuracies, misidentified compounds, and contaminants. Janvier and colleagues, in a 2018 analysis in Talanta, reported significant impurities and contamination above ICH toxicity limits in falsified polypeptide products. A 2026 review by Mendias and Awan, published in Sports Medicine, on approved and unapproved peptides used in clinical wellness contexts documented the clinical context in which these compounds operate — emphasizing the distinction between compounds with clinical oversight and those without. These are not theoretical risks. The documented contamination rate in non-prescription peptide products is high enough that obtaining any injectable compound outside the prescription pathway carries meaningful, quantifiable risk.

The grey market framing problem

Tuckson and colleagues, writing in the New England Journal of Medicine in 2017, examined the scope and quality considerations of telehealth, including online prescribing — noting that providers prescribing without patient-specific information represent a qualitatively different risk from those who conduct full clinical evaluations. The same framing applies to the grey market for research peptides: access without oversight is not equivalent to access through a regulated system, regardless of how it is marketed.

What to Test Before Starting Peptide Therapy

Establishing a baseline before any peptide therapy evaluation gives both the patient and the prescriber interpretable data. Without a baseline, changes in biomarkers during therapy cannot be attributed to the compound; and without pre-therapy values, any adverse signals — elevated IGF-1, impaired glucose, or declining kidney function — cannot be distinguished from pre-existing conditions.

• IGF-1: The primary downstream marker of growth hormone axis activity. The Endocrine Society specifies IGF-1 testing as part of the pre-prescribing evaluation for GH-axis peptides — both to establish the baseline and to confirm that growth hormone deficiency or insufficiency is clinically present; at Superpower, members can review their IGF-1 biomarker guide for baseline context.
• Fasting glucose: Growth hormone secretagogues can impair insulin sensitivity. A pre-therapy fasting glucose value documents baseline glycemic status and enables detection of any GH-related glucose signal during therapy.
• HbA1c: Provides a 90-day integrated glucose picture that a single fasting glucose measurement cannot. A baseline HbA1c is essential context for interpreting any glucose changes that emerge during GH secretagogue therapy.
• eGFR and creatinine: Kidney function affects drug clearance and is a relevant safety parameter for injectable peptide therapy. Baseline eGFR establishes whether any renal signal during therapy represents a new finding or a pre-existing pattern.
• Lipid panel including triglycerides: GH secretagogues and GLP-1 agonists both influence lipid metabolism. Baseline triglycerides, LDL, and HDL values allow prescribers to track metabolic response accurately.
• hs-CRP: Systemic inflammation affects peptide pharmacodynamics and is relevant baseline context. A pre-therapy hs-CRP measurement helps distinguish therapy-related changes from pre-existing inflammatory patterns.
• Complete metabolic panel: Liver function (AST, ALT), kidney function (creatinine, BUN), and electrolytes all constitute relevant safety parameters before initiating injectable peptide therapy.

Establishing these values before any peptide therapy evaluation means that if a prescriber does determine candidacy is appropriate, the clinical picture is already interpretable. That principle — objective data before any clinical decision, and ongoing data to interpret response — is central to Superpower's approach to preventive health.

What Your Labs May Show During Peptide Therapy

For growth hormone secretagogue therapy, providers typically monitor IGF-1 as the primary pharmacodynamic marker — an increase toward or within the age-adjusted reference range is consistent with pituitary response to the peptide. Fasting glucose and HbA1c are monitored for any GH-related insulin resistance signal; clinical guidelines recommend reassessment within the first weeks of therapy and at regular intervals thereafter. A 2006 RCT of CJC-1295 by Teichman, Frohman, and colleagues, published in the Journal of Clinical Endocrinology and Metabolism, documented 2-fold to 10-fold increases in mean GH concentrations alongside IGF-1 elevation in a monitored clinical context — illustrating the kind of lab trajectory providers use to assess GH peptide response.

For GLP-1 receptor agonist therapy, glucose and HbA1c trend downward in metabolic responders, and lipid panels often show improvement over the first several months. In either peptide class, labs that move outside the reference range — elevated IGF-1, rising glucose, or declining eGFR — are clinical signals that warrant prescriber review and potential dose adjustment. Superpower's primary offering is comprehensive biomarker testing; members who meet clinical criteria may also be connected with licensed providers for evaluation and, where appropriate and available in the member's state, prescription of compounded peptide formulations with ongoing lab monitoring. For baseline evaluation before any peptide therapy, the complete guide to biomarker testing explains the markers relevant to metabolic and hormonal health.

Regulatory Status and Compounding Access

FDA approval status

As of April 2026, a limited set of peptide compounds carry FDA approval for specific indications. Semaglutide is FDA-approved for type 2 diabetes (Ozempic), chronic weight management (Wegovy), and cardiovascular risk reduction in adults with obesity. Tesamorelin is FDA-approved specifically for HIV-associated lipodystrophy; its use in other populations is not FDA-endorsed. Bremelanotide (Vyleesi, PT-141) is FDA-approved for hypoactive sexual desire disorder in premenopausal women. A 2020 review by Mayer and Lynch, published in Annals of Pharmacotherapy, summarized the FDA approval process and prescribing context for bremelanotide — an example of how an FDA-approved prescription peptide reaches patients through a defined regulatory pathway. Compounds including sermorelin, CJC-1295, and ipamorelin are not FDA-approved for any indication but may be legally compounded under 503A for patient-specific use where statutory 503A conditions are met. As of April 2026, BPC-157 is classified as an FDA Category 2 bulk drug substance following the February 2026 reclassification. Category 2 means the FDA has identified significant safety risks with the substance; 503A pharmacies that compound a Category 2 substance do so without the FDA's enforcement-discretion protections and at materially elevated risk of FDA enforcement action. The FDA's 503A bulk drug substance list remains under active review, and compound-specific status may change. Readers considering TB-500 (thymosin beta-4) or BPC-157 should check the individual compound page for current regulatory status, which may have changed since publication.

Where an FDA-approved peptide drug exists, Section 503A(b)(1)(D) permits 503A compounding of that drug only when it appears on the FDA Drug Shortage List. Compounded semaglutide, compounded tirzepatide, and similar GLP-1 receptor agonists are legally compoundable only during shortage periods; when the reference drug is no longer on shortage, 503A compounding of copies is not permitted except under narrow clinical-difference exceptions. Readers should check current FDA shortage status before assuming a compounded GLP-1 is legally available.

Compounding access and 503A

As of April 2026, licensed 503A compounding pharmacies may prepare patient-specific compounded peptide formulations for compounds that are not on the FDA's Category 1 or Category 2 restricted lists. Gianturco and Mattingly, in a 2020 review published in the Journal of the American Pharmacists Association, distinguished 503A patient-specific compounding from 503B outsourcing facilities — 503A requires an individual patient prescription from a licensed practitioner, while 503B facilities produce larger batches for hospital and clinical use. Qureshi and colleagues' 2014 paper in the Journal of Managed Care & Specialty Pharmacy provided a foundational review of the sterile compounding regulatory framework that governs how compounding pharmacies operate. State regulations add an additional layer: prescribers must be licensed in the patient's state, and the dispensing 503A compounding pharmacy must hold both a home-state pharmacy license and, where it ships across state lines, a non-resident pharmacy permit in the patient's state. Compounding-specific state rules — including sterile compounding inspection standards and bulk-substance restrictions that may go beyond federal rules — also apply.

Cost and insurance framing

FDA-approved peptide therapies prescribed for their approved indications — semaglutide for obesity, for example — may qualify for insurance coverage with prior authorization. Off-label and compounded peptide formulations are typically not covered by health insurance. HSA or FSA eligibility for peptide therapy depends on the specific compound, account type, and whether the expense qualifies under IRS Section 213. Many compounded peptide formulations, including those offered through Superpower's platform, are not HSA/FSA eligible. Patients should verify eligibility with their plan administrator before assuming coverage. The evaluation process through a licensed provider includes a clinical consultation and relevant lab work. Superpower's peptide-therapy evaluation flow typically includes baseline lab work before any prescription and ongoing biomarker monitoring during therapy.

How to Evaluate a Provider for Peptide Therapy

Access to peptide therapy through a qualified, licensed provider is what separates a clinically supervised approach from the unregulated grey market. A legitimate prescriber conducts a clinical evaluation, reviews relevant baseline laboratory data before prescribing, documents a clinical rationale, partners with a state-licensed 503A compounding pharmacy (ideally one that holds voluntary accreditation such as PCAB accreditation from ACHC), and has a defined monitoring plan. The telehealth setting does not diminish these requirements; a 2022 study by Dubin and colleagues in the International Journal of Impotence Research described a telemedicine model for testosterone replacement therapy that mirrors the Superpower approach — evaluation, baseline labs, prescription, and follow-up.

Questions to ask before starting with any provider:

• Do you require baseline lab work before prescribing? Which markers do you assess for this specific compound?
• How will you monitor my response? At what intervals will you reassess lab values during therapy?
• Which compounding pharmacy do you use? Is it licensed as a 503A pharmacy in your state, and does it hold voluntary accreditation (e.g., PCAB accreditation from ACHC) demonstrating USP 797 compliance?
• Is this compound FDA-approved for the indication you are prescribing it for, or is it off-label? What does the evidence base look like?
• What is the plan if I experience an adverse effect? What signals would prompt a dose change or discontinuation?
• How do you distinguish the clinical profile that warrants this prescription from someone who does not meet your prescribing criteria?

For evaluation and candidacy assessment, Superpower's primary offering is comprehensive biomarker testing; members who meet clinical criteria may also be connected with licensed providers who conduct clinical evaluations, order baseline lab work, and supervise ongoing monitoring where candidacy is appropriate and available in the member's state.

IMPORTANT SAFETY INFORMATION: This article discusses peptide compounds with varying FDA approval statuses, including compounds available by prescription through licensed compounding pharmacies (sermorelin, CJC-1295/ipamorelin) and FDA-approved peptide therapeutics (semaglutide, tesamorelin, bremelanotide). Some compounds referenced, including BPC-157, are classified as FDA Category 2 bulk drug substances as of April 2026, restricting their compounding. The compounds discussed in this article are prescription-only in the US; none should be self-administered without evaluation and prescription by a licensed healthcare provider.

Peptide therapy carries risks that vary by compound class. Growth hormone secretagogues may impair insulin sensitivity and require baseline and follow-up glucose and IGF-1 monitoring. Injectable compounds carry sterility and immunogenicity risks. Products obtained outside the 503A prescription-compounding pathway have documented contamination risks including incorrect dosing and toxic metal contamination, as described by Deconinck and colleagues in a 2018 peer-reviewed analysis.

Superpower's primary offering is comprehensive biomarker testing; members who meet clinical criteria may also be connected with licensed providers for evaluation and, where appropriate and available in the member's state, prescription of compounded peptide formulations with ongoing lab monitoring. Superpower does not prescribe peptide therapy directly. For FDA-approved prescribing information for tesamorelin, see the DailyMed entry for tesamorelin. For semaglutide, see the DailyMed entry for semaglutide.

Disclaimer: This page discusses multiple compounds with varying FDA approval statuses. Some compounds mentioned may not be FDA-approved for human use. Superpower's primary offering is comprehensive biomarker testing; for some compounds discussed, members who meet clinical criteria may be connected with licensed providers in the member's state for evaluation and, where appropriate, prescription of compounded formulations. See individual compound pages for specific availability and regulatory status. This content is for educational and informational purposes only.